Finance

Lists
ALMKT:EPA
Mauna Kea Technologies SA
0,15 €
-1,36%
(-0,0020) 1D
28 қыр., 17:35:20 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for ALMKT...
Open
0,15 €
High
0,15 €
Low
0,14 €
Mkt. cap
27,79 млн
Avg. vol.
518,28 м.
Volume
145,50 м.
P/E ratio
1,19
52-wk high
0,23 €
52-wk low
0,07 €
EPS
0,12 €
Shares outstanding
195,26 млн
No. of employees
59
Open
0,15 €
High
0,15 €
Low
0,14 €
Mkt. cap
27,79 млн
Avg. vol.
518,28 м.
Volume
145,50 м.
P/E ratio
1,19
52-wk high
0,23 €
52-wk low
0,07 €
EPS
0,12 €
Shares outstanding
195,26 млн
No. of employees
59
Profile
Mauna Kea Technologies is a global medical device company focused on endomicroscopy, the field of microscopic imaging during endoscopy procedures. The company researches, develops and markets tools to visualize, detect, and rule out abnormalities including malignant and pre-malignant tumors or lesions in the gastrointestinal and pulmonary tracts. The company makes Cellvizio, a probe-based Confocal Laser Endomicroscopy system, which provides physicians and researchers with real-time access to histological information during standard endoscopy procedures through high-resolution cellular imaging of internal tissues. Cellvizio is used in medical applications such as gastrointestinal endoscopy, pulmonology and urology to help physicians diagnose lesions and make accurate treatment decisions in real-time. Cellvizio went public in July 2011 and trades on the Euronext Paris exchange. Wikipedia
About Mauna Kea Technologies SA
CEOSacha Loiseau
Employees59
Founded2000
Headquarters-
SectorMedical device
Last report
2026 ж. 15 қаң.
Fiscal period
Q4 2025
EPS / Est. (EUR)
- / -
Revenue / Est. (EUR)
2,44 млн / -
Fiscal Q4 2025 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in EUR
2025 ж. нау.
2025 ж. мау.
2025 ж. қыр.
2025 ж. жел.
Revenue
2,02 млн
2,02 млн
2,44 млн
2,44 млн
Cost of goods sold
396,00 м.
396,00 м.
528,00 м.
528,00 м.
Cost of revenue
396,00 м.
396,00 м.
528,00 м.
528,00 м.
Research and development expenses
818,50 м.
818,50 м.
861,00 м.
861,00 м.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,90 млн
1,90 млн
1,89 млн
1,89 млн
Operating expense
3,02 млн
3,02 млн
3,11 млн
3,11 млн
Total operating expenses
3,41 млн
3,41 млн
3,64 млн
3,64 млн
Operating income
-1,40 млн
-1,40 млн
-1,20 млн
-1,20 млн
Other non operating income
-695,00 м.
-695,00 м.
10,84 млн
10,84 млн
EBT including unusual items
-2,31 млн
-2,31 млн
7,69 млн
7,69 млн
EBT excluding unusual items
-2,20 млн
-2,20 млн
8,06 млн
8,06 млн
Income tax expense
28,00 мың
28,00 мың
-35,50 мың
-35,50 мың
Effective tax rate
-1,21%
-1,21%
-0,46%
-0,46%
Other operating expenses
83,00 мың
83,00 мың
92,00 мың
92,00 мың
Net income
-2,33 млн
-2,33 млн
7,72 млн
7,72 млн
Net profit margin
-115,83%
-115,83%
316,50%
316,50%
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
-
Interest expense
-6,50 мың
-6,50 мың
-490,50 м.
-490,50 м.
Net interest expenses
-6,50 мың
-6,50 мың
-490,50 м.
-490,50 м.
Depreciation and amortization charges
-
-
-
-
EBITDA
-1,35 млн
-1,35 млн
-1,11 млн
-1,11 млн
Gain or loss from assets sale
-
-
281,00 м.
281,00 м.
AI content may include mistakes. Learn more
Google қолданбалары